COVRE, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 2.322
EU - Europa 1.562
AS - Asia 297
OC - Oceania 4
AF - Africa 2
SA - Sud America 2
Totale 4.189
Nazione #
US - Stati Uniti d'America 2.315
IE - Irlanda 457
IT - Italia 343
RU - Federazione Russa 194
GB - Regno Unito 170
SE - Svezia 122
CN - Cina 110
SG - Singapore 102
FR - Francia 84
UA - Ucraina 70
VN - Vietnam 54
DE - Germania 46
FI - Finlandia 30
ES - Italia 29
CA - Canada 5
HK - Hong Kong 4
IN - India 4
AL - Albania 3
AU - Australia 3
AZ - Azerbaigian 3
PH - Filippine 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
HR - Croazia 2
IL - Israele 2
NL - Olanda 2
PA - Panama 2
TR - Turchia 2
ZA - Sudafrica 2
AM - Armenia 1
BE - Belgio 1
BO - Bolivia 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
ID - Indonesia 1
IM - Isola di Man 1
JO - Giordania 1
JP - Giappone 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 4.189
Città #
Dublin 455
Fairfield 405
Santa Clara 226
Ashburn 189
Woodbridge 183
Seattle 169
Cambridge 157
Houston 154
Wilmington 150
Southend 143
Singapore 81
Siena 70
Princeton 69
Jacksonville 68
New York 68
Dong Ket 50
Shanghai 45
Ann Arbor 44
San Mateo 36
San Diego 32
Chandler 31
Beijing 29
Málaga 29
Rome 29
Helsinki 27
Dearborn 25
Florence 25
Milan 19
Moscow 17
Fremont 15
London 12
Palermo 12
Sesto Fiorentino 10
Empoli 8
Guangzhou 6
Los Angeles 6
Montevarchi 6
Redwood City 6
Asciano 5
Labico 5
Padova 5
San Francisco 5
San Giovanni Valdarno 5
Toronto 5
Trieste 5
Boardman 4
Catania 4
Hefei 4
Hong Kong 4
Phoenix 4
Altamura 3
Ascoli Piceno 3
Lappeenranta 3
Lavis 3
Norwalk 3
Novara 3
Tirana 3
Abu Dhabi 2
Baku 2
Carmignano 2
Chiswick 2
Chiusdino 2
Ferentino 2
Gallarate 2
Gavirate 2
Hounslow 2
Livorno 2
Nanjing 2
Newark 2
Pistoia 2
Pontedera 2
Salerno 2
Stockholm 2
Tel Aviv 2
Torino 2
Udine 2
Warsaw 2
Washington 2
Zagreb 2
Almaty 1
Amman 1
Arienzo 1
Arlington 1
Athens 1
Auckland 1
Bagno a Ripoli 1
Baotou 1
Bari 1
Berlin 1
Bishkek 1
Bologna 1
Brisbane 1
Brussels 1
Cascina 1
Centurion 1
Chicago 1
Colombo 1
Columbus 1
Dallas 1
Figline Valdarno 1
Totale 3.247
Nome #
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 164
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 150
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 136
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 134
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 132
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 128
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 127
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 125
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 123
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 121
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 110
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 109
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 108
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 105
Immunotherapy targeting immune check-point(s) in brain metastases 104
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 102
Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens 100
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 99
Epigenetically-regulated Tumor-Associated Antigens in melanoma 98
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 96
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients 89
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma 88
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 88
null 87
Epigenetics meets immune checkpoints 86
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 80
Challenges in lung cancer therapy during the COVID-19 pandemic 79
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 77
null 75
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 75
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status 69
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 68
Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. 67
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 66
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 58
null 56
A novel microRNA signature for the detection of melanoma by liquid biopsy 55
Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy, 5:1103-1116, 2013 53
Epigenetic mechanisms in cancer formation and progression 51
COVID and Lung Cancer 50
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 49
Immunotherapy of brain metastases: breaking a "dogma" 45
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 44
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 43
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 42
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy 41
The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology 38
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 38
Whole genome methylation profiles and survival of melanoma patients 37
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 36
The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma 36
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 33
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 32
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 29
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 14
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? 13
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer 10
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome 9
Totale 4.377
Categoria #
all - tutte 18.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.786


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020811 0 0 0 0 0 133 153 172 140 96 39 78
2020/2021885 26 95 59 105 94 93 41 130 33 72 32 105
2021/2022443 13 59 40 8 8 30 20 18 29 56 63 99
2022/2023537 50 38 106 49 11 97 19 32 45 32 41 17
2023/2024793 35 20 76 28 22 222 252 26 27 12 27 46
2024/2025653 60 42 142 91 218 100 0 0 0 0 0 0
Totale 4.377